DrugBiological
Onfekafusp alfa clinical trials
Also written L19TNF.
- studies test it
- 15
- open now
- 8
- in phase 3
- 2
- first study started
- 2012
Keep track of what changes. Save the onfekafusp alfa studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
15 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 1 |
| 2024 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 11
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 15 · Other 0
Often tested with
Tested in the same studies.
Darleukin (5) · Lomustine (4) · Doxorubicin (2) · Temozolomide (2) · Daromun (2)
Studies
Open first, then newest update. How each study uses onfekafusp alfa is read from its arms, and is right about nine times in ten.
Testing it · 15
- Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma PatientsRecruitingPhase 2Philogen S.p.A.NCT06284590Written as L19TNF
- L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)RecruitingPhase 2Philogen S.p.A.NCT07227350Written as L19TNF
- A Study to Evaluate the Safety and Efficacy of L19TNF With Alkylating Chemotherapy for Patients With Recurrent IDH-mutant Astrocytoma or OligodendrogliomaNot yet recruitingPhase 2Philogen S.p.A.NCT07120984Written as L19TNF
- A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First ProgressionRecruitingPhase 1/2Philogen S.p.A.NCT04573192Written as L19TNF
- A Study Comparing the Efficacy of L19TNF+Doxorubicin vs Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue SarcomaRecruitingPhase 3Philogen S.p.A.NCT04650984Written as Onfekafusp alfa
- Intratumoral Administration of Daromun in Non-melanoma Skin Cancer PatientsRecruitingPhase 2Philogen S.p.A.NCT04362722Written as L19IL2 +L19TNF
- Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed GlioblastomaRecruitingPhase 1/2Philogen S.p.A.NCT04443010Written as Onfekafusp alfa
- Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients (FIBROSARC USA)RecruitingPhase 2Philogen S.p.A.NCT03420014Written as L19TNF plus doxorubicin
- A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or RecurrenceActive, not recruitingPhase 2Philogen S.p.A.NCT06336291Written as L19TNF
- Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue SarcomaActive, not recruitingPhase 2Philogen S.p.A.NCT04733183Written as onfekafusp alfa
- Neoadjuvant L19IL2/L19TNF- Pivotal StudyActive, not recruitingPhase 3Philogen S.p.A.NCT02938299Written as L19IL2 + L19TNF
- Dose Finding Study of L19TNF and Doxorubicin in Patients With STSActive, not recruitingPhase 1Philogen S.p.A.NCT04032964Written as L19TNF
- Safety and Efficacy of Different Administration Sequences of L19TNF With Lomustine in Glioblastoma at First ProgressionWithdrawnPhase 1Philogen S.p.A.NCT05304663Written as Onfekafusp alfa
- Safety and Efficacy of L19TNF in Patients With Isocitrate Dehydrogenase (IDH) Wildtype WHO Grade III / IV Glioma at First RelapseCompletedPhase 1/2Philogen S.p.A.NCT03779230Written as L19TNF
- Intratumoral Administration of L19IL2/L19TNFCompletedPhase 2Philogen S.p.A.NCT02076633Written as L19IL2+L19TNF
Codes
What other systems call onfekafusp alfa · ClinicalTrials.gg INT015278
- UNII (FDA) 6HXC0O6JMVONFEKAFUSP ALFAOne source FDA
- NCI Thesaurus C166939Onfekafusp AlfaOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 6HXC0O6JMV | ONFEKAFUSP ALFA | One source FDA |
| NCI Thesaurus | C166939 | Onfekafusp Alfa | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.